Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Curadh MTR
Pennsylvania, United Statescuradhmtr.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Curadh MTR is advancing preclinical radiopharmaceutical oncology programs targeting solid tumors, based on proprietary molecularly targeted radiation platforms and strategic isotope supply agreements; clinical studies are anticipated in 2025-2026.[1][3]
- Therapeutic areas
- Oncology
- Modalities
- RadiopharmaceuticalMolecularly targeted radiation therapyBiologic
- Industry
- Biotech
02
Partnerships
NorthStar Medical Radioisotopes (strategic supply/clinical collaboration for actinium-225 radiopharmaceuticals)[2][8]Alpha Fusion (joint venture for astatine-211 based radiopharmaceutical development)[4][7][9]
Beyond the preview
Go deeper on Curadh MTR.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Curadh MTR.